Compare Inovio Pharmaceuticals Inc (INO) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.11 (market cap $119.42M), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $48.51 (market cap $73.20B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 613× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days on average.
| INO | VTIP | |
|---|---|---|
Market Cap | $119.42M | $73.20B |
Volume | 2,789,649 | 2,480,668 |
Sector | Health | — |
52-Week High | $2.65 | $50.46 |
52-Week Low | $0.66 | $48.38 |
Typical Hold Time | 43 Days | 91 Days |
Enterprise Value | $90.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 3.54% on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $84.95 million in 2025 on minimal revenue of $65,340, with negative profitability metrics, but has beaten EPS estimates in recent quarters. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107.
The investment case hinges on regulatory approval of INO-3107, with a consensus price target of $2.75 implying significant upside. However, extreme financial losses, high cash burn, and dependence on dilutive financing pose substantial risks. Analyst sentiment is cautiously optimistic but reflects high uncertainty.
VTIP trades at $48.46, up 0.08% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The ETF, focused on short-term inflation-protected securities, shows strong institutional interest, with firms like NewEdge Advisors increasing positions by 45.5% in Q2 2026 (SEC filing, September 2026). Recent news highlights its role in hedging inflation amid rising energy prices and Fed rate hikes.
The outlook for VTIP is supported by its inflation-hedging appeal in a high-rate environment, but risks include interest rate sensitivity and competition from other TIPS ETFs. Wall Street sentiment is cautious yet constructive, given its low-cost structure and short-duration focus, positioning it as a defensive allocation for investors seeking inflation protection without significant rate risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
